Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase - Mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation

Arthritis and Rheumatism

Volumn 56, Issue 5, 2007, Pages 1549-1558

  Karsdal, Morten Asser ^a,b   Sumer, Eren Ufuk ^a   Wulf, Helle ^a   Madsen, Suzi H ^a   Christiansen, Claus ^c   Fosang, Amanda J ^d   Sondergaard, Bodil Cecilie ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Pharmos Bioscience   (Denmark)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE; CARBOXY TERMINAL TELOPEPTIDE; CYCLIC AMP; CYTOKINE; EPITOPE; FORSKOLIN; GLYCOSAMINOGLYCAN POLYSULFATE; ISOBUTYLMETHYLXANTHINE; MATRIX METALLOPROTEINASE; ONCOSTATIN M; TOLONIUM CHLORIDE; TUMOR NECROSIS FACTOR;

ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL FUNCTION; CHONDROPROTECTION; CULTURE MEDIUM; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; STAINING; TISSUE CULTURE; ZYMOGRAPHY;

1-METHYL-3-ISOBUTYLXANTHINE; ANIMALS; CALCITONIN; CARTILAGE, ARTICULAR; CATTLE; CELLS, CULTURED; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; FEMALE; FORSKOLIN; GLYCOSAMINOGLYCANS; MATRIX METALLOPROTEINASES; ONCOSTATIN M; OSTEOARTHRITIS; PHOSPHODIESTERASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248569434     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22599     Document Type: Article

References (41)

1. Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone? [editorial]. Arthritis Rheum 2004;50:341-4.
2. Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl 2000;60:6-8.
3. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-206.
4. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540-51.
5. Sexton PM, Findlay DM, Martin TJ. Calcitonin. Curr Med Chem 1999;6:1067-93.
6. Purdue BW, Tilakaratne N, Sexton PM. Molecular pharmacology of the calcitonin receptor. Receptors Channels 2002;8:243-55.
7. Hilton JM, Dowton M, Houssami S, Sexton PM. Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J Endocrinol 2000;166:213-26.
8. Sondergaard BC, Olsen AK, Sumer EU, Ovist P, Bagger YZ, Tanko LB, et al. Calcitonin stimulates proteoglycan and collagen type II biosynthesis in articular cartilage ex vivo [abstract]. Osteoarthritis Cartilage 2005;13 Suppl A:142.
9. Chen TC, Hinton DR, Zidovetzki R, Hofman FM. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest 1998;78:165-74.
10. Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. Structure and function of aggrecan. Cell Res 2002;12:19-32.
11. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005;434:644-8.
12. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005;434:648-52.
13. Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Brauer R, et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 2006;14:738-48.
14. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 2005;3:553-80.
15. Hui W, Rowan AD, Richards CD, Cawston TE. Oncostatin M in combination with tumor necrosis factor α induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 2003;48:3404-18.
16. Fosang AJ, Last K, Gardiner P, Jackson DC, Brown L. Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase- derived aggrecan fragments: detection of fragments in human synovial fluids. Biochem J 1995;310 (Pt 1):337-43.
17. Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA, et al. MMP and non-MMP mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 2006. E-pub ahead of print.
18. Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006;14:101-13.
19. Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, et al. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 1999;344 (Pt 1):61-8.
20. Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, et al. Transforming growth factor-β controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 2003;278:44975-87.
21. Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 2002;277:44061-7.
22. Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, et al. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthritis Cartilage 2006; 14:617-24.
23. Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, Ovist P, et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 2006;14:759-68.
24. D'Angelo M, Yan Z, Nooreyazdan M, Pacifici M, Sarment DS, Billings PC, et al. MMP-13 is induced during chondrocyte hypertrophy. J Cell Biochem 2000;77:678-93.
25. Lemaitre V, Jungbluth A, Eeckhout Y. The recombinant catalytic domain of mouse collagenase-3 depolymerizes type I collagen by cleaving its aminotelopeptides. Biochem Biophys Res Commun 1997;230:202-5.
26. Chockalingam PS, Zeng W, Morris EA, Flannery CR. Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2). Arthritis Rheum 2004; 50:2839-48.
27. Henriksen K, Sorensen MG, Nielsen RH, Gram J, Schaller S, Dziegiel MH, et al. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J Bone Miner Res 2006;21:58-66.
28. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 1992;267:19470-4.
29. Van Meurs JB, van Lent PL, van de Loo AA, Holthuysen AE, Bayne EK, Singer II, et al. Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis. Ann Rheum Dis 1999;58:350-6.
30. Van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, van den Berg WB. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 1999;42:1128-39.
31. Van Meurs JB, van Lent PL, Singer II, Bayne EK, van de Loo FA, van den Berg WB. Interleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope VDIPEN in antigen-induced arthritis. Arthritis Rheum 1998;41: 647-56.
32. Martin TJ, Quinn JM, Gillespie MT, Ng KW, Karsdal MA, Sims NA. Mechanisms involved in skeletal anabolic therapies. Ann N Y Acad Sci 2006;1068:458-70.
33. Karsdal MA, Andersen TA, Bonewald L, Christiansen C. Matrix metalloproteinases (MMPs) safeguard osteoblasts from apoptosis during trans-differentiation into osteocytes: MT1-MMP maintains osteocyte viability. DNA Cell Biol 2004;23:155-65.
34. Tenor H, Hedbom E, Hauselmann HJ, Schudt C, Hatzelmann A. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes - functional importance of phosphodiesterase 4. Br J Pharmacol 2002;135:609-18.
35. Geng Y, Zhou L, Thompson WJ, Lotz M. Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes. J Biol Chem 1998;273:27484-91.
36. Bednar MS, Hubbard JR, Steinberg JJ, Broner FA, Sledge CB. Cyclic AMP-regulating agents inhibit endotoxin-mediated cartilage degradation. Biochem J 1987;244:63-8.
37. Malemud CJ, Papay RS, Hering TM. Forskolin stimulates aggrecan gene expression in cultured bovine chondrocytes. Am J Ther 1996;3:120-8.
38. Malemud CJ, Papay RS, Hasler P, Kammer GM. The effect of nonsteroidal anti-inflammatory drugs on cAMP-dependent protein kinase-mediated phosphorylation by human chondrocytes in culture. Clin Exp Rheumatol 1994;12:149-56.
39. Malemud CJ, Mills TM, Shuckett R, Papay RS. Stimulation of sulfated-proteoglycan synthesis by forskolin in monolayer cultures of rabbit articular chondrocytes. J Cell Physiol 1986;129:51-9.
40. Malemud CJ, Papay RS. Stimulation of cyclic AMP in chondrocyte cultures: effects on sulfated-proteoglycan synthesis. FEBS Lett 1984;167:343-51.
41. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006;14:13-29.